Gaps in evidence on treatment of male osteoporosis: a Research Agenda

References

• Sarafrazi N, Wambogo EA, Shepherd JA. Osteoporosis or low bone mass in older adults: United States, 2017–2018. NCHS Data Brief, no 405. Hyattsville, MD: National Center for Health Statistics. 2021. doi: 10.15620/cdc:103477.
   Google Scholar
• Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726–1733. doi: 10.1007/s00198-006-0172-4.
   PubMed Web of Science ®Google Scholar
• Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353(9156):878–882. doi: 10.1016/S0140-6736(98)09075-8.
   PubMed Web of Science ®Google Scholar
• Iacovino JR. Mortality outcomes after osteoporotic fractures in men and women. J Insur Med. 2001;33(4):316–320.
   PubMedGoogle Scholar
• Kannegaard PN, van der Mark S, Eiken P, et al. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing. 2010;39(2):203–209. doi: 10.1093/ageing/afp221.
   PubMed Web of Science ®Google Scholar
• Pouresmaeili F, Kamalidehghan B, Kamarehei M, et al. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018;14:2029–2049. doi: 10.2147/TCRM.S138000.
   PubMed Web of Science ®Google Scholar
• Yang CY, Cheng-Yen Lai J, Huang WL, et al. Effects of sex, tobacco smoking, and alcohol consumption osteoporosis development: evidence from Taiwan biobank participants. Tob Induc Dis. 2021;19:52. doi: 10.18332/tid/136419.
   PubMed Web of Science ®Google Scholar
• Jasuja GK, Travison TG, Davda M, et al. Age trends in estradiol and estrone levels measured using liquid chromatography tandem mass spectrometry in community-dwelling men of the Framingham Heart Study. J Gerontol A Biol Sci Med Sci. 2013;68(6):733–740. doi: 10.1093/gerona/gls216.
   PubMed Web of Science ®Google Scholar
• Eriksson AL, Perry JRB, Coviello AD, et al. Genetic determinants of circulating estrogen levels and evidence of a causal effect of estradiol on bone density in men. J Clin Endocrinol Metab. 2018;103(3):991–1004. doi: 10.1210/jc.2017-02060.
   PubMed Web of Science ®Google Scholar
• Gennari L, Khosla S, Bilezikian JP. Estrogen and fracture risk in men. J Bone Miner Res. 2008;23(10):1548–1551. doi: 10.1359/jbmr.0810c.
   PubMed Web of Science ®Google Scholar
• Hammes SR, Levin ER. Impact of estrogens in males and androgens in females. J Clin Invest. 2019;129(5):1818–1826. doi: 10.1172/JCI125755.
   PubMed Web of Science ®Google Scholar
• Guggenbuhl P. Osteoporosis in males and females: is there really a difference? Joint Bone Spine. 2009;76(6):595–601. doi: 10.1016/j.jbspin.2009.10.001.
   PubMed Web of Science ®Google Scholar
• Alswat KA. Gender disparities in osteoporosis. J Clin Med Res. 2017;9(5):382–387. doi: 10.14740/jocmr2970w.
   PubMedGoogle Scholar
• Van der Klift M, De Laet CE, McCloskey EV, et al. The incidence of vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res. 2002;17(6):1051–1056. doi: 10.1359/jbmr.2002.17.6.1051.
   PubMed Web of Science ®Google Scholar
• Seeman E, Duan Y, Fong C, et al. Fracture site-specific deficits in bone size and volumetric density in men with spine or hip fractures. J Bone Miner Res. 2001;16(1):120–127. doi: 10.1359/jbmr.2001.16.1.120.
   PubMed Web of Science ®Google Scholar
• Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med. 2008;358(14):1474–1482. doi: 10.1056/NEJMcp0707217.
   PubMed Web of Science ®Google Scholar
• Conley RB, Adib G, Adler RA, et al. Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition. J Bone Miner Res. 2020;35(1):36–52. doi: 10.1002/jbmr.3877.
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Newberry SJ, Diamant A, et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med. 2014;161(10):711–723. doi: 10.7326/M14-0317.
   PubMed Web of Science ®Google Scholar
• Nayak S, Greenspan SL. Osteoporosis treatment efficacy for men: a systematic review and meta-analysis. J Am Geriatr Soc. 2017;65(3):490–495. doi: 10.1111/jgs.14668.
   PubMed Web of Science ®Google Scholar
• Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604–610. doi: 10.1056/NEJM200008313430902.
   PubMed Web of Science ®Google Scholar
• Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367(18):1714–1723. doi: 10.1056/NEJMoa1204061.
   PubMed Web of Science ®Google Scholar
• Ringe JD, Faber H, Farahmand P, et al. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int. 2006;26(5):427–431. doi: 10.1007/s00296-005-0004-4.
   PubMed Web of Science ®Google Scholar
• Ringe JD, Farahmand P, Faber H, et al. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int. 2009;29(3):311–315. doi: 10.1007/s00296-008-0689-2.
   PubMed Web of Science ®Google Scholar
• Zullo AR, Zhang T, Lee Y, et al. Effect of bisphosphonates on fracture outcomes among frail older adults. J Am Geriatr Soc. 2019;67(4):768–776. doi: 10.1111/jgs.15725.
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16(5):510–516. doi: 10.1007/s00198-004-1713-3.
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18(1):9–17. doi: 10.1359/jbmr.2003.18.1.9.
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Teglbjærg CS, Ho P-R, et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab. 2015;100(4):1335–1342. doi: 10.1210/jc.2014-4079.
   PubMed Web of Science ®Google Scholar
• Clinical Trials Results: Abaloparatide. [Accessed 2023 May 11]. Available at: https://clinicaltrials.gov/ct2/show/results/NCT03512262.
   Google Scholar
• Jasuja GK, Rose AJ. Who gets testosterone? Patient characteristics associated with testosterone prescribing in the veteran affairs system: a cross-sectional study. J Gen Intern Med. 2017;32(10):1075. doi: 10.1007/s11606-017-4113-z.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–2559. doi: 10.1210/jc.2009-2354.
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Arver S, Moncada I, et al. How to help the aging male? Current approaches to hypogonadism in primary care. Aging Male. 2012;15(4):187–197. doi: 10.3109/13685538.2012.729110.
   PubMed Web of Science ®Google Scholar
• Snyder P. Testosterone treatment of late-onset hypogonadism - benefits and risks. Rev Endocr Metab Disord. 2022;23(6):1151–1157. doi: 10.1007/s11154-022-09712-1.
   PubMed Web of Science ®Google Scholar
• Ng Tang Fui M, Hoermann R, Bracken K, et al. Effect of testosterone treatment on bone microarchitecture and bone mineral density in men: a 2-year RCT. J Clin Endocrinol Metab. 2021;106(8):e3143–e3158. doi: 10.1210/clinem/dgab149.
   PubMed Web of Science ®Google Scholar
• Dorr B, Abdelaziz A, Karram M. Subcutaneous testosterone pellet therapy for reversal of male osteoporosis: a review and case report. Aging Male. 2023;26(1):2181953.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med. 2017;177(4):471–479. doi: 10.1001/jamainternmed.2016.9539.
   PubMed Web of Science ®Google Scholar
• Fink JE, Hackney AC, Matsumoto M, et al. Mobility and biomechanical functions in the aging male: testosterone and the locomotive syndrome. Aging Male. 2020;23(5):403–410. doi: 10.1080/13685538.2018.1504914.
   PubMed Web of Science ®Google Scholar
• Martin-Fernandez M, Garzon-Marquez FM, Diaz-Curiel M, et al. Comparative study of the effects of osteoprotegerin and testosterone on bone quality in male orchidectomised rats. Aging Male. 2020;23(3):189–201. doi: 10.1080/13685538.2018.1499082.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons from the testosterone trials. Endocr Rev. 2018;39(3):369–386. doi: 10.1210/er.2017-00234.
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male. 2012;15(2):96–102. doi: 10.3109/13685538.2011.631230.
   PubMed Web of Science ®Google Scholar
• Bouloux PM, Legros JJ, Elbers JM, et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study. Aging Male. 2013;16(2):38–47. doi: 10.3109/13685538.2013.773420.
   PubMed Web of Science ®Google Scholar
• Kenny AM, Kleppinger A, Annis K, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58(6):1134–1143. doi: 10.1111/j.1532-5415.2010.02865.x.
   PubMed Web of Science ®Google Scholar
• Permpongkosol S, Tantirangsee N, Ratana-Olarn K. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints. J Sex Med. 2010;7(11):3765–3774. doi: 10.1111/j.1743-6109.2010.01994.x.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Tolra J, Torremade J, di Gregorio S, et al. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome. Andrology. 2013;1(4):570–575. doi: 10.1111/j.2047-2927.2013.00090.x.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Konaka H, Koh E, et al. Effects of testosterone replacement therapy on hypogonadal men with osteopenia or osteoporosis: a subanalysis of a prospective randomized controlled study in Japan (EARTH study). Aging Male. 2017;20(3):139–145. doi: 10.1080/13685538.2017.1303829.
   PubMed Web of Science ®Google Scholar
• Wang YJ, Zhan JK, Huang W, et al. Effects of low-dose testosterone undecanoate treatment on bone mineral density and bone turnover markers in elderly male osteoporosis with low serum testosterone. Int J Endocrinol. 2013;2013:570413. doi: 10.1155/2013/570413.
   PubMed Web of Science ®Google Scholar
• Rogol AD, Tkachenko N, Bryson N. Natesto, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men. Andrology. 2016;4(1):46–54. doi: 10.1111/andr.12137.
   PubMed Web of Science ®Google Scholar
• Mohamad NV, Soelaiman IN, Chin KY. A concise review of testosterone and bone health. Clin Interv Aging. 2016;11:1317–1324. doi: 10.2147/CIA.S115472.
   PubMed Web of Science ®Google Scholar
• Andrici J, Tio M, Eslick GD. Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer. Aliment Pharmacol Ther. 2012;36(8):708–716. doi: 10.1111/apt.12041.
   PubMed Web of Science ®Google Scholar
• Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98(11):4483–4492. doi: 10.1210/jc.2013-1597.
   PubMed Web of Science ®Google Scholar
• Chiu WY, Chien JY, Yang WS, et al. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. J Clin Endocrinol Metab. 2014;99(8):2729–2735. doi: 10.1210/jc.2013-4119.
   PubMed Web of Science ®Google Scholar
• Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27(12):2544–2550. doi: 10.1002/jbmr.1719.
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int. 2015;26(12):2773–2783. doi: 10.1007/s00198-015-3234-7.
   PubMed Web of Science ®Google Scholar
• Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364(18):1728–1737. doi: 10.1056/NEJMoa1010650.
   PubMed Web of Science ®Google Scholar
• Schilcher J, Koeppen V, Aspenberg P, et al. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015;86(1):100–107. doi: 10.3109/17453674.2015.1004149.
   PubMed Web of Science ®Google Scholar
• Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab. 2019;104(5):1623–1630. doi: 10.1210/jc.2019-00192.
   PubMed Web of Science ®Google Scholar
• Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–1622. doi: 10.1210/jc.2019-00221.
   PubMed Web of Science ®Google Scholar
• Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res. 2012;27(2):243–254. doi: 10.1002/jbmr.1494.
   PubMed Web of Science ®Google Scholar
• Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res. 2015;30(5):934–944. doi: 10.1002/jbmr.2442.
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–2938. doi: 10.1001/jama.296.24.2927.
   PubMed Web of Science ®Google Scholar
• Adams AL, Li BH, Ryan DS, et al. Do drug holidays reduce atypical femur fracture risk? Results from the Southern California Osteoporosis Cohort Study (SOCS). Presented at: The 2018 American Society for Bone and Mineral Research Annual Meeting; 2018 Sep 28 - Oct 1 Montreal, Quebec, Canada.
   Google Scholar
• Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2016;31(10):1910. doi: 10.1002/jbmr.2918.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190–198. doi: 10.1002/jbmr.3337.
   PubMed Web of Science ®Google Scholar
• Fink HA, MacDonald R, Forte ML, et al. Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann Intern Med. 2019;171(1):37–50. doi: 10.7326/M19-0533.
   PubMed Web of Science ®Google Scholar
• Siu A, Allore H, Brown D, et al. National institutes of health pathways to prevention workshop: research gaps for long-term drug therapies for osteoporotic fracture prevention. Ann Intern Med. 2019;171(1):51–57. doi: 10.7326/M19-0961.
   PubMed Web of Science ®Google Scholar
• Antonelli M, Einstadter D, Magrey M. Screening and treatment of osteoporosis after hip fracture: comparison of sex and race. J Clin Densitom. 2014;17(4):479–483. doi: 10.1016/j.jocd.2014.01.009.
   PubMed Web of Science ®Google Scholar
• Feldstein AC, Nichols G, Orwoll E, et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int. 2005;16(8):953–962. doi: 10.1007/s00198-005-1950-0.
   PubMed Web of Science ®Google Scholar
• Harper CM, Fitzpatrick SK, Zurakowski D, et al. Distal radial fractures in older men. A missed opportunity? J Bone Joint Surg Am. 2014;96(21):1820–1827. doi: 10.2106/JBJS.M.01497.
   PubMedGoogle Scholar
• Jennings LA, Auerbach AD, Maselli J, et al. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc. 2010;58(4):650–657. doi: 10.1111/j.1532-5415.2010.02769.x.
   PubMed Web of Science ®Google Scholar
• Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002;162(19):2217–2222. doi: 10.1001/archinte.162.19.2217.
   PubMedGoogle Scholar
• Riley RL, Carnes ML, Gudmundsson A, et al. Outcomes and secondary prevention strategies for male hip fractures. Ann Pharmacother. 2002;36(1):17–23. doi: 10.1345/aph.1A094.
   PubMed Web of Science ®Google Scholar
• Adler RA. Osteoporosis in men. 2020 May 31. In: feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Grossman A, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
   Google Scholar
• Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–1809. doi: 10.1056/NEJMoa074941.
   PubMed Web of Science ®Google Scholar
• Speich B, von Niederhausern B, Schur N, et al. Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data. J Clin Epidemiol. 2018;96:1–11. doi: 10.1016/j.jclinepi.2017.12.018.
   PubMed Web of Science ®Google Scholar
• Foody JM, Mendys PM, Liu LZ, et al. The utility of observational studies in clinical decision making: lessons learned from statin trials. Postgrad Med. 2010;122(3):222–229. doi: 10.3810/pgm.2010.05.2161.
   PubMed Web of Science ®Google Scholar
• Sackett DL. Clinical epidemiology: a basic science for clinical medicine. 2nd ed. Boston: Little Brown; 1991.
   Google Scholar